Ironwood Pharmaceuticals (IRWD) PT Lowered to $17 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St climbs as oil slips; SpaceX spectrum deal weighs on telecoms
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment deteriorates further in October
- CoreWeave stock drops on dilution fears and debt concerns
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
- Anthropic launches cyber defense program for infrastructure and open-source
UPDATE: Credit Suisse Downgrades Ironwood Pharmaceuticals (IRWD) to Neutral
November 7, 2018 5:15 AM EST(Updated - November 7, 2018 7:56 AM EST)
(updated to add analyst comments)
Credit Suisse analyst Vamil Divan downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Outperform to Neutral with a price target of $14.00 (from $22.00) citing disappointing updates on key product Linzess and what... More
JPMorgan Downgrades Ironwood Pharmaceuticals (IRWD) to Underweight
November 7, 2018 5:10 AM ESTJPMorgan analyst Eric Joseph downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Underweight with a price target of $11.00 (from $20.00).
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $12.78 yesterday.
... More


